MedTrace Logo

Gadopiclenol vs Gadoxetate MRI for Liver Lesions

NCT06596616 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2026-04-22

No results posted yet for this study

Summary

The overall purpose of this study is to establish noninferiority of gadopiclenol MRI compared to gadoxetate MRI in terms of image quality and lesion detection/conspicuity in patients undergoing clinically indicated liver MRI in a prospective study. The research will be utilizing MRI; with enrollment goal of 75 subjects over the course of two years.

Conditions

  • Liver Lesion

Interventions

OTHER

Radiology

Radiology - MRI Scans

OTHER

Gadopiclenol

Gadopiclenol is a new macrocyclic gadolinium-based contrast agent (GBCA)

Sponsors & Collaborators

Principal Investigators

  • Sara Lewis, MD · Icahn School of Medicine at Mount Sinai

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06596616 on ClinicalTrials.gov